SK Bioscience Co Ltd
KRX:302440

Watchlist Manager
SK Bioscience Co Ltd Logo
SK Bioscience Co Ltd
KRX:302440
Watchlist
Price: 52 500 KRW -5.41% Market Closed
Market Cap: 4.1T KRW
Have any thoughts about
SK Bioscience Co Ltd?
Write Note

SK Bioscience Co Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SK Bioscience Co Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
SK Bioscience Co Ltd
KRX:302440
Cash from Financing Activities
-â‚©89.6B
CAGR 3-Years
-288%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash from Financing Activities
-â‚©196.8B
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
-20%
Green Cross Corp
KRX:006280
Cash from Financing Activities
â‚©82.8B
CAGR 3-Years
14%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
H
Hugel Inc
KOSDAQ:145020
Cash from Financing Activities
-â‚©181.7B
CAGR 3-Years
-91%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Financing Activities
-â‚©17.7B
CAGR 3-Years
-39%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash from Financing Activities
â‚©32.5B
CAGR 3-Years
-43%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

SK Bioscience Co Ltd
Glance View

Market Cap
4T KRW
Industry
Biotechnology

SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.

Intrinsic Value
39 027.34 KRW
Overvaluation 26%
Intrinsic Value
Price

See Also

What is SK Bioscience Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-89.6B KRW

Based on the financial report for Dec 31, 2023, SK Bioscience Co Ltd's Cash from Financing Activities amounts to -89.6B KRW.

What is SK Bioscience Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-288%

Over the last year, the Cash from Financing Activities growth was -351%. The average annual Cash from Financing Activities growth rates for SK Bioscience Co Ltd have been -288% over the past three years .

Back to Top